TherapeuticsMD (NASDAQ:TXMD) is set to issue its quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.
TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business had revenue of $3.80 million during the quarter, compared to analyst estimates of $4.23 million. During the same period last year, the business posted ($0.10) EPS. TherapeuticsMD’s revenue was down 11.6% compared to the same quarter last year. On average, analysts expect TherapeuticsMD to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
TherapeuticsMD stock traded down $0.05 during midday trading on Wednesday, reaching $4.89. The company’s stock had a trading volume of 107,114 shares, compared to its average volume of 2,874,047. TherapeuticsMD has a fifty-two week low of $4.30 and a fifty-two week high of $7.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. The company has a market cap of $1.18 billion, a P/E ratio of -13.54 and a beta of 1.40.
TXMD has been the subject of a number of recent analyst reports. BidaskClub downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Monday, July 30th. Oppenheimer set a $12.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Monday, July 30th. Finally, JPMorgan Chase & Co. set a $11.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $13.88.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.